TSXV - Free Realtime Quote CAD

XORTX Therapeutics Inc. (XRTX.V)

1.1500

-0.0500

(-4.17%)

As of 9:30:00 AM EDT. Market Open.

XORTX Announces Update for Discussion with the FDA

● Type B Meeting Discussion to Accelerate XRx-026 for Gout to NDA ● CALGARY, Alberta, March 19, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, is pleased to provide an update regarding communications with the US Food and Drug Administration (the “FDA”). At the request of the FDA a type B me

GlobeNewswire 23 days ago

XRTX
-5.46%
XORTX Commences Gout Program NDA Discussions with the FDA

● Type C Meeting Requested to Accelerate XRx-026 for Gout to NDA ● CALGARY, Alberta, Feb. 24, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces that it has submitted a Type C meeting request with the US Food and Drug Administration (the “FDA”) regarding the Company’s XRx-026 program

GlobeNewswire last month

XRTX
-5.46%
XORTX to Present at Microcap Conference

CALGARY, Alberta, Jan. 29, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces attendance and presentation at the Microcap Conference hosted by DealFlow Events on January 28 through 30, 2025 in Atlantic City, NJ. Attendance at this conference continues outreach to the investment commu

GlobeNewswire 2 months ago

XRTX
-5.46%
XORTX Announces Change of Auditor

CALGARY, Alberta, Jan. 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces the Company has changed its auditor from Smythe LLP, Chartered Professional Accountants (“Former Auditor”) to Davidson & Company LLP, Chartered Professional Accountants, (“Successor Auditor”) effective Janua

GlobeNewswire 2 months ago

XRTX
-5.46%
XORTX Adds Late Stage Gout Program to Pipeline

XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding NDA filingCALGARY, Alberta, Jan. 06, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces the launch of a new late stage program to treat gout. The new drug development pro

GlobeNewswire 3 months ago

XRTX
-5.46%
XORTX Strengthens Executive Team

Dr. Michael Bumby joins XORTX as Chief Financial OfficerCALGARY, Alberta, Dec. 19, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Dr. Michael Bumby, a biotech/pharma industry veteran, as its Chief Financial Officer replacing James Fairbairn, the Company’s current Chief Financial Officer. Dr

GlobeNewswire 3 months ago

XRTX
-5.46%
XORTX Announces Presentation at the Rare and Genetic Disease Summit

CALGARY, Alberta, Dec. 12, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce a presentation by Dr. Allen Davidoff at the Rare and Genetic Kidney Disease Summit, in Boston, Massachusetts at 10:30 am ET, Thursday December 12, 2024. The presentation entitled “Autosomal Dominant Poly

GlobeNewswire 3 months ago

XRTX
-5.46%
XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024

● Health consequences of chronically high uric acid and xanthine oxidase in polycystic kidney disease in rats, mice and humans ● CALGARY, Alberta, Oct. 24, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the acceptance of an abstract submitted to the American Society of Nephrol

GlobeNewswire 5 months ago

XRTX
-5.46%
XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement

CALGARY, Alberta, Oct. 18, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, today announced that it has closed its registered direct offering and concurrent private placement, announced on October 17, 2024, for the purchase and sale of 810,810 common shares (or pre-funded warrants in lieu thereof) in

GlobeNewswire 5 months ago

XRTX
-5.46%
XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement

CALGARY, Alberta, Oct. 17, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has entered into securities purchase agreements with institutional investors for the purchase and sale of 810,810 common shares (or common share equivalents in lieu thereof) in a registered direct offering an

GlobeNewswire 5 months ago

XRTX
-5.46%
XORTX Initiates Precision Medicine Program

Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine MetabolismCALGARY, Alberta, Oct. 09, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the Company has initiated a precision medicine program. On August 2

GlobeNewswire 5 months ago

XRTX
-5.46%
XORTX Announces Results of Annual and Special Meeting of Shareholders

CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held Thursday, September 12, 2024. A total of 889,288 common shares of the Company were represented at the Meeting, represen

GlobeNewswire 6 months ago

XRTX
-5.46%
XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A

CALGARY, Alberta, Sept. 12, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has refiled its management’s discussion and analysis (“MD&A”) for the financial year ended December 31, 2023 and for the interim period ended June 30, 2024 as a result of a continuous disclosure review by th

GlobeNewswire 6 months ago

XRTX
-5.46%
XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders

CALGARY, Alberta, Sept. 06, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, reminds shareholders of the upcoming deadline to vote at the Company’s Annual General and Special Meeting (the "Meeting"), which is scheduled to be held on September 12, 2024. The Board of Directors of XORTX recommends that S

GlobeNewswire 6 months ago

XRTX
-5.46%
Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders

CALGARY, Alberta, Sept. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has recommended Shareholders vote “FOR” all the proposed resolutions at the upcoming Annual and Special Meeti

GlobeNewswire 7 months ago

XRTX
-5.46%
XORTX Highlights Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism

● Xanthine oxidase reported to modulate progression of chronic kidney disease, diabetic kidney disease, polycystic kidney disease, and other indications ● CALGARY, Alberta, Aug. 29, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to report that recent peer-reviewed, independent, published

GlobeNewswire 7 months ago

XRTX
-5.46%
XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders

CALGARY, Alberta, Aug. 23, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the management information circular (the “Circular”) for the annual and special meeting (the “Meeting”) of shareholders is now available on the Company’s website at https://www.xortx.com/investors/news-e

GlobeNewswire 7 months ago

XRTX
-5.46%
XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024

Health consequences of over active xanthine oxidase may accelerated PKD progressionCALGARY, Alberta, Aug. 20, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the acceptance of an abstract submitted to the American Society of Nephrology (the “ASN”). The abstract entitled "Xanth

GlobeNewswire 7 months ago

XRTX
-5.46%
XORTX to Present at BIO International Convention 2024

CALGARY, June 04, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its participation in the BIO International Convention 2024, being held June 3rd through 6th, 2024. Dr. Allen Davidoff, XORTX’s CEO, will present an overview on the Company, including the Company’s progress to dat

GlobeNewswire 10 months ago

XRTX
-5.46%
XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO

CALGARY, Alberta, May 17, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its press releases of March 11 and April 30, 2024, the Company has received TSX Venture Exchange (“TSXV”) approval to amend the terms of the balance of outstanding common share purchase warrants (“Warr

GlobeNewswire 10 months ago

XRTX
-5.46%

Performance Overview

Return	XRTX.V	S&P/TSX Composite index (^GSPTSE)
YTD	-31.95%	-4.29%
1-Year	-76.53%	+6.58%
3-Year	-99.42%	+8.14%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

XORTX Therapeutics Inc. (XRTX.V)

XORTX Announces Update for Discussion with the FDA

XORTX Commences Gout Program NDA Discussions with the FDA

XORTX to Present at Microcap Conference

XORTX Announces Change of Auditor

XORTX Adds Late Stage Gout Program to Pipeline

XORTX Strengthens Executive Team

XORTX Announces Presentation at the Rare and Genetic Disease Summit

XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024

XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement

XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement

XORTX Initiates Precision Medicine Program

XORTX Announces Results of Annual and Special Meeting of Shareholders

XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A

XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders

Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders

XORTX Highlights Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine Metabolism

XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders

XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024

XORTX to Present at BIO International Convention 2024

XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO

Performance Overview